Table 1.
The origin, morphology, genetic mutation, tumorigenic capability, and metastatic potential of OS cell lines
| Cell line | Origin | Morphology | Gene mutation | Days to form 1.5–2 cm3 tumor | Meta rate (%) |
Refs. | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor suppressor | Oncogene | ||||||||||
| CDKN2A | TP53 | RB1 | PTEN | BRAF | KRAS | ||||||
| HOS | OS of a 13-y-o girl | E | m/m | m/m | w/w | w/w | w/w | w/w | No tumor in 8 weeks | 0% | [58, 64] |
| 143B | HOS cells, transformed by KRAS | Mixed E/F | m/m | m/m | w/w | w/w | w/w | m/w | 27 | 100% | [64, 69] |
| MNNG | HOS cells, induced by MNNG | Mixed E/F | m/m | m/m | w/w | w/w | w/w | w/w | 32 | 100% | [64, 66, 70] |
| SaOS-2 | OS of a 11-y-o girl | E | w/w | m/m | m/m | w/w | w/w | w/w | 95 | 100% | [62, 63] |
| SaOS-LM7 | Lung Meta from SaOS-2 cells in mouse tibia | E | w/w | m/m | m/m | w/w | w/w | w/w | 65 | 100% | [71] |
| MG-63 | Fibroblastic OS of a 14-y-o boy | F | m/m | m/m | w/w | w/w | w/w | w/w | 170 | 0% | [59] |
| U-2 OS | Sarcoma in tibia of a 15-y-o girl | E | w/w | w/w | w/w | w/w | w/w | w/w | No tumor in 150 days | 0% | [60, 61, 72] |
| K7 (K8, …, K12) | Spontaneous OS in BALB/c mouse | O | NA | NA | NA | NA | NA | NA | NA | 33.3% (K12) | [37, 38, 45] |
| K7M2 |
Lung meta From K7 cells in mouse tibia |
O | NA | NA | NA | NA | NA | NA | 30 days to reach 0.8 cm3 | 93.3% | [36, 37, 39, 40, 45] |
| Dunn | Spontaneous OS from C3H/HeN mouse tail | E | NA | NA | NA | NA | NA | NA | 25 | 100% | [42, 45] |
| UMR 106-01 | 32P-induced tumor in rat | E | NA | NA | NA | NA | NA | NA | 25 days to reach 0.15 cm3 | 100% | [32, 47] |
| D-17 | Lung Meta of OS in a 11-y-o female poodle | E | NA | NA | NA | NA | NA | NA | No tumor in 79 days | NA | [53] |
m/m, mutant/mutant homozygous; w/w, wild type/wild type normal alleles; m/w, mutant/wild type heterozygous; NA, not available; E, epithelial; F, fibroblast; O, osteoblast; Meta, metastasis